Antibody-based therapies are revolutionizing cancer treatment and experience a steady increase from preclinical and clinical pipelines to market share. While the clinical success of monoclonal antibodies is frequently limited by low response rates, treatment resistance and various other factors, multispecific antibodies open up new prospects by addressing tumor complexity as well as immune response actuation potently improving safety and efficacy. Novel antibody approaches involve simultaneous binding of two antigens on one cell implying increased specificity and reduced tumor escape for dual tumor-associated antigen targeting and enhanced and durable cytotoxic effects for dual immune cell-related antigen targeting. This article reviews antibody and cell-based therapeutics for oncology with intrinsic dual targeting of either tumor cells or immune cells. As revealed in various preclinical studies and clinical trials, dual targeting molecules are promising candidates constituting the next generation of antibody drugs for fighting cancer.

中文翻译：

---

安全总比后悔好：用于癌症免疫治疗的双靶向抗体

基于抗体的疗法正在彻底改变癌症治疗，并经历从临床前和临床管道到市场份额的稳步增长。虽然单克隆抗体的临床成功常常受到低反应率、治疗耐药性和各种其他因素的限制，但多特异性抗体通过解决肿瘤复杂性以及免疫反应激活，有效提高安全性和有效性，开辟了新的前景。新型抗体方法涉及两个抗原同时结合在一个细胞上，这意味着肿瘤相关抗原双重靶向的特异性增加，肿瘤逃逸减少，免疫细胞相关抗原双重靶向的细胞毒性作用增强且持久。本文回顾了基于肿瘤细胞的抗体和细胞疗法，其内在双重靶向肿瘤细胞或免疫细胞。正如各种临床前研究和临床试验所揭示的，双靶向分子是构成下一代抗癌抗体药物的有希望的候选者。